AD/PD 2022 | The use of Alzheimer’s disease plasma biomarkers in the clinic: further research needed

Pamela Lukasewicz Ferreira, PhD, University of Pittsburgh, Pittsburgh, PA, describes that although novel plasma biomarkers, such as amyloid and tau, have had good initial results in diagnosing Alzheimer’s disease in a laboratory setting but more research is required before they are used in a clinical setting. Dr Lukasewicz Ferreira highlights that one of the main issues was studies – including hers – using mainly white cohorts: studies with more diverse populations are crucial to see if factors like race and ethnicity influence biomarkers. This interview took place at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases hosted in Barcelona, Spain.